1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited

INDSWFTLAB.NS
Ind-Swift Laboratories LimitedIN flagNational Stock Exchange of India
157.11
INR
-4.99
- -
13.64BMarket Cap
Ind-Swift Laboratories Limited
INDSWFTLAB.NS
(National Stock Exchange of India)

Recent

price

157.11

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
352.25
392.85
289.79
235.6
161.23
159.47
168.31
169.19
161.81
157.62
150.85
175.8
204.33
289.26
85.38
- -
69.57
Revenue per Share
30.39
24.86
-30.07
-29.79
-29.14
-14.33
-9.2
4.88
6.19
-4.28
-0.53
-0.36
8.06
91.18
37.24
- -
34.16
Basic EPS, GAAP
-55.92
-48.26
-25.74
8.44
14.44
10.71
14.91
11.52
-17.07
23.06
22.09
22.32
30.78
-44
-13.84
- -
- -
Free Cash Flow per Basic Share
0.95
0.95
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
15.03
102.66
64.14
32.02
3.06
-11.18
-11.89
-6.22
-0.74
-2.87
-2.78
-3.09
5.16
-54.3
-10.23
- -
-10.57
Book Value per Share
145.04
154.7
146.05
111.77
84.03
70.52
76.31
92.59
109.43
121.22
100.53
101.52
115.41
135.66
172.8
- -
178.63
Tangible Book Value per Share
29
36
39
41
41
41
43
45
47
49
59
59
59
59
67
- -
65
Basic Weighted Avg Shares
10,370
14,092
11,361
9,651
6,605
6,532
7,162
7,625
7,566
7,796
8,913
10,387
12,073
17,091
5,742
6,413
4,526
Sales/Revenue/Turnover
13.71
10.5
1.82
0.21
3.85
5.11
4.82
8.11
5.89
9.38
12.45
8.9
15.04
14.19
-5.46
2.26
-8.17
Operating Margin (%)
409
399
544
658
843
847
883
866
1,040
901
873
1,310
574
804
245
30,604
191
Depreciation Expense
895
892
-1,179
-1,220
-1,194
-587
-391
220
289
-212
-31
-21
476
5,388
2,505
414
2,222
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
38.93
41.73
- -
117.48
117.15
44.72
9.86
2.82
15.76
3.17
Effective Tax Rate (%)
8.63
6.33
-10.38
-12.64
-18.07
-8.98
-5.46
2.88
3.83
-2.72
-0.35
-0.21
3.94
31.52
43.62
6.46
49.1
Profit Margin (%)
3,553
3,668
3,603
3,589
870
-1,454
-1,733
-976
4,801
5,400
6,297
7,409
7,934
5,265
6,448
7,195
6,448
Working Capital
5,994
7,110
8,182
9,644
8,161
6,842
5,920
5,205
9,656
8,913
8,846
8,483
7,531
1,990
259
123
259
LT Debt
5,781
8,237
8,534
7,252
5,945
5,174
5,313
5,490
5,878
6,406
6,034
6,009
6,819
8,121
11,730
13,840
11,730
Total Equity
- -
- -
- -
- -
- -
- -
- -
2.39
1.66
- -
-1.18
-1
6.42
17.17
-2.84
0.95
-3.27
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
3.85
7.99
- -
-1.94
-1.85
10.44
159
-383.77
107.43
1,020.98
Return on Capital (%)
235.89
43.23
-38.05
-63.78
-166.16
- -
- -
- -
- -
- -
- -
- -
- -
223.91
96.43
- -
731.5
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'25
ST Debt
55
- -
149
LT Borrowings
109
- -
257
LT Finance Leases
- -
- -
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
59
- -
61
Market Capitalization
7,970
6,984
5,463

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'25
Total Current Assets
5,868
- -
8,653
Cash, Cash Equivalents & STI
4,385
- -
4,514
Accounts Receivable, Net
575
- -
1,645
Inventories
93
- -
1,142
Total Current Liabilities
1,644
- -
2,206
Payables & Accruals
- -
- -
- -
ST Debt
55
- -
149
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.08%
18.92%
17.99%
Free Cash Flow
-65.47%
-39.79%
69.29%
Net Income, GAAP
-186.77%
-290.32%
-83.47%
Sales/Revenue/Turnover
5.23%
3.92%
11.68%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,103
2,897
2,875
3,933
17,091
2025
332
1,483
1,288
1,424
5,742
2026
1,526
1,509
1,698
- -
6,413

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.92
5.36
3.29
- -
91.18
2025
0.16
0.67
-0.82
33.04
37.24
2026
1
1.17
1.81
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Sun Pharmaceutical Industries Limited (SUNPHARMA.BO)
Organigram Global Inc. (OGI)
Orchid Ventures, Inc. (ORVRF)
Dr. Reddy's Laboratories Limited (DRREDDY.BO)
Sentry Petroleum Ltd (SPLM)
New Leaf Ventures Inc (NLV.CN)
Business
Ind-Swift Laboratories Limited manufactures active pharmaceutical ingredients, intermediates and formulations through group collaborations for global regulatory markets including the US, Europe and emerging regions. The company, founded in 1995 and headquartered in Chandigarh, India, specializes in APIs across therapeutic areas such as cardiovascular health including Atorvastatin Calcium and Ranolazine; antihistaminic; antidiabetic; antipsychotic including Aripiprazole; antimigraine; Parkinson's disease including Ropinirole HCl; antineoplastic including Letrozole and Anastrozole; ADHD symptoms; analgesics; alcohol abstinence; bone resorption inhibitors including Risedronate Sodium; and holds global leadership in macrolide antibiotics including Clarithromycin and its derivatives; it also provides contract research and manufacturing services with a 40,000 sq ft R&D center in Mohali, Punjab that has developed over 50 APIs and filed multiple DMFs. Facilities feature approvals from USFDA, EDQM, ANVISA, KFDA and others, supporting exports to regulated and row markets via six modern manufacturing sites. Recent developments include the sale of its API and CRAMS businesses to PI Industries via slump sale effective March 18, 2024; merger with Ind Swift Limited approved by NCLT and effective August 8, 2025 with appointed date March 31, 2024, involving allotment of preference shares and conversion of equity warrants; approval at June 2024 EGM for business expansion and investments up to INR 1,500 million in wholly owned subsidiaries by December 2027 including strategic greenfield and brownfield opportunities in India and abroad, plus INR 500 million in subsidiary loans or equity by December 2026; and strategic asset sales such as plant machinery to ANG Lifesciences for Rs 38.40 crores contributing to robust FY2025 profits of Rs 256 crores standalone.